Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Boren

Allergy & Immunology Bakersfield, CA Medical Doctor

NPI 1720067598 CMS profile 305361

2121 17Th St, Bakersfield, CA 93301

Open in the dashboard

General payments

$54,930

544 records reported · program years 2019–2025

Research payments

$6,884

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,351,405 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Eric Boren of Bakersfield, CA is reported in the CMS Open Payments database as having received $54,930 across 544 general payments and $6,884 in research payments paid to them. Separately, studies naming them as principal investigator received $2,351,405 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,245 93
2024 General $1,462 74
2024 Research $1,178 8
2023 General $17,275 79
2023 Research $1,655 9
2022 General $10,464 76
2021 General $16,056 71
2020 General $5,593 75
2020 Research $4,050 1
2019 General $1,835 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Boren
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Eric Boren were reported at $2,245. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Eric Boren Allergy & Immunology median Middle half National median
2019 $1,835 $594 $163–$1,512 $163
2020 $5,593 $426 $106–$1,233 $114
2021 $16,056 $638 $157–$1,708 $132
2022 $10,464 $790 $205–$1,961 $149
2023 $17,275 $852 $220–$2,147 $160
2024 $1,462 $865 $203–$2,267 $164
2025 $2,245 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $41,996 112 payments
  2. Novartis Pharmaceuticals Corporation $1,834 29 payments
  3. AstraZeneca Pharmaceuticals LP $1,609 79 payments
  4. Octapharma USA, Inc. $1,387 23 payments
  5. AstraZeneca UK Limited $1,253 5 payments
  6. Regeneron Healthcare Solutions, Inc. $1,159 45 payments
  7. Pharming Healthcare, Inc. $1,157 18 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $884 50 payments
  9. CSL Behring $542 24 payments
  10. BioCryst US Sales Co., LLC $327 16 payments
  11. Other $2,782 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,282 25 payments
  2. Food and Beverage $12,195 507 payments
  3. Travel and Lodging $2,259 7 payments
  4. Education $170 4 payments
  5. Consulting Fee $24 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $23,884 48 payments
  2. CUTAQUIG $1,373 23 payments
  3. RUCONEST $1,157 18 payments
  4. DUPIXENT Inflammation And Immunology $766 31 payments
  5. CUVITRU $552 30 payments
  6. TEZSPIRE $465 17 payments
  7. NUCALA $413 32 payments
  8. DUPIXENT Immunology $400 23 payments
  9. DUPIXENT Immunology And Inflammation $393 14 payments
  10. TAKHZYRO $379 23 payments
  11. Other $5,936 303 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,050 1 payment
  2. Sanofi US Services Inc. $1,655 9 payments
  3. Regeneron Pharmaceuticals, Inc. $1,178 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,144

Median for Allergy/ Immunology: 449

Drug cost

$330,120

Median for Allergy/ Immunology: $169,700

Branded share of claims

33.5%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 22 $82,916
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 98 $80,170
Tezspire Tezepelumab-Ekko Brand 13 $54,780
Nucala Mepolizumab Brand 11 $41,544
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $16,491
Breo Ellipta Fluticasone/Vilanterol Brand 16 $9,542
Epinephrine Generic 24 $6,630
Advair Hfa Fluticasone Propion/Salmeterol Brand 15 $6,421
Fluticasone Propionate Hfa Fluticasone Propionate Brand 11 $3,869
Azelastine Hcl Generic 130 $3,651

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$169,098

Of which drugs: $46

Medicare patients

375

Average age 71

Services billed

17,006

253 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 54%
Ischemic heart disease 33%
Diabetes 28%
COPD 25%
Depression 21%
Osteoporosis 20%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 52 $38

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$294 22 —
NUCALA
$218 11 —
AIRSUPRA
$122 — —
TEZSPIRE
$109 13 —
XOLAIR
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record